PRELUDE THERAPEUTICS INC Research and Development Expense
PRELUDE THERAPEUTICS INC (PRLD) reported Research and Development Expense of $16.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC research and development expense for the quarter ending 2026-06-30 was $16.13M, a 37.44% decline year-over-year.
- PRELUDE THERAPEUTICS INC research and development expense for the quarter ending 2026-03-31 was $13.60M, a 52.80% decline year-over-year.
- PRELUDE THERAPEUTICS INC research and development expense for the quarter ending 2025-12-31 was $17.99M, a 43.10% decline year-over-year.
- PRELUDE THERAPEUTICS INC research and development expense for the quarter ending 2025-09-30 was $21.71M, a 26.31% decline year-over-year.
- PRELUDE THERAPEUTICS INC research and development expense for fiscal 2025 was $94.30M, a 20.08% decline from fiscal 2024.
- PRELUDE THERAPEUTICS INC research and development expense for fiscal 2024 was $118.00M, a 14.12% increase from fiscal 2023.
- PRELUDE THERAPEUTICS INC research and development expense for fiscal 2023 was $103.39M, a 11.31% increase from fiscal 2022.
- PRELUDE THERAPEUTICS INC research and development expense for fiscal 2022 was $92.89M, a 7.04% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $16.13M 10-Q · filed 2026-08-11 | $29.73M 10-Q · filed 2026-08-11 | $47.72M derived: sum of 3 quarters · filed 2026-08-11 | $69.43M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $13.60M 10-Q · filed 2026-05-12 | $31.59M derived: sum of 2 quarters · filed 2026-05-12 | $53.30M derived: sum of 3 quarters · filed 2026-05-12 | $79.08M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $17.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $39.70M derived: sum of 2 quarters · filed 2026-03-10 | $65.48M derived: sum of 3 quarters · filed 2026-08-11 | $94.30M 10-K · filed 2026-03-10 |
| 2025-09-30 | $21.71M 10-Q · filed 2025-11-12 | $47.49M derived: sum of 2 quarters · filed 2026-08-11 | $76.31M 10-Q · filed 2025-11-12 | $107.93M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $25.78M 10-Q · filed 2026-08-11 | $54.60M 10-Q · filed 2026-08-11 | $86.22M derived: sum of 3 quarters · filed 2026-08-11 | $115.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $28.82M 10-Q · filed 2026-05-12 | $60.44M derived: sum of 2 quarters · filed 2026-05-12 | $89.89M derived: sum of 3 quarters · filed 2026-05-12 | $119.40M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $31.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $61.08M derived: sum of 2 quarters · filed 2026-03-10 | $90.59M derived: sum of 3 quarters · filed 2026-03-10 | $118.00M 10-K · filed 2026-03-10 |
| 2024-09-30 | $29.46M 10-Q · filed 2025-11-12 | $58.97M derived: sum of 2 quarters · filed 2025-11-12 | $86.38M 10-Q · filed 2025-11-12 | $116.71M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $29.51M 10-Q · filed 2025-08-14 | $56.92M 10-Q · filed 2025-08-14 | $87.25M derived: sum of 3 quarters · filed 2025-08-14 | $113.51M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $27.41M 10-Q · filed 2025-05-06 | $57.74M derived: sum of 2 quarters · filed 2025-05-06 | $84.00M derived: sum of 3 quarters · filed 2025-05-06 | $108.97M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $30.33M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $56.59M derived: sum of 2 quarters · filed 2025-03-10 | $81.56M derived: sum of 3 quarters · filed 2025-03-10 | $103.39M 10-K · filed 2025-03-10 |
| 2023-09-30 | $26.26M 10-Q · filed 2024-11-06 | $51.23M derived: sum of 2 quarters · filed 2024-11-06 | $73.06M 10-Q · filed 2024-11-06 | $98.93M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $24.97M 10-Q · filed 2024-08-12 | $46.80M 10-Q · filed 2024-08-12 | $72.67M derived: sum of 3 quarters · filed 2024-08-12 | $95.56M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | $21.83M 10-Q · filed 2024-05-07 | $47.70M derived: sum of 2 quarters · filed 2024-05-07 | $70.59M derived: sum of 3 quarters · filed 2024-05-07 | $91.90M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $25.87M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | $48.76M derived: sum of 2 quarters · filed 2024-02-15 | $70.07M derived: sum of 3 quarters · filed 2024-02-15 | $92.89M 10-K · filed 2024-02-15 |
| 2022-09-30 | $22.89M 10-Q · filed 2023-11-01 | $44.20M derived: sum of 2 quarters · filed 2023-11-01 | $67.02M 10-Q · filed 2023-11-01 | $92.20M derived: sum of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | $21.31M 10-Q · filed 2023-08-03 | $44.13M 10-Q · filed 2023-08-03 | $69.31M derived: sum of 3 quarters · filed 2023-08-03 | $92.03M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $22.82M 10-Q · filed 2023-05-08 | $48.00M derived: sum of 2 quarters · filed 2023-05-08 | $70.72M derived: sum of 3 quarters · filed 2023-05-08 | $93.13M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $25.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $47.90M derived: sum of 2 quarters · filed 2023-03-15 | $70.31M derived: sum of 3 quarters · filed 2023-03-15 | $86.78M 10-K · filed 2023-03-15 |
| 2021-09-30 | $22.72M 10-Q · filed 2022-11-14 | $45.13M derived: sum of 2 quarters · filed 2022-11-14 | $61.60M 10-Q · filed 2022-11-14 | $76.17M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $22.41M 10-Q · filed 2022-08-09 | $38.88M 10-Q · filed 2022-08-09 | $53.45M derived: sum of 3 quarters · filed 2022-08-09 | $68.74M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $16.47M 10-Q · filed 2022-05-10 | $31.04M derived: sum of 2 quarters · filed 2022-05-10 | $46.34M derived: sum of 3 quarters · filed 2022-05-10 | $56.11M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $14.57M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $29.86M derived: sum of 2 quarters · filed 2022-03-17 | $39.64M derived: sum of 3 quarters · filed 2022-03-17 | $48.18M 10-K · filed 2022-03-17 |
| 2020-09-30 | $15.29M 10-Q · filed 2021-11-12 | $25.07M derived: sum of 2 quarters · filed 2021-11-12 | $33.60M 10-Q · filed 2021-11-12 | $42.45M derived: sum of 4 quarters · filed 2021-11-12 |
| 2020-06-30 | $9.78M 10-Q · filed 2021-08-12 | $18.31M 10-Q · filed 2021-08-12 | $27.16M derived: sum of 3 quarters · filed 2021-08-12 | $32.65M derived: sum of 4 quarters · filed 2021-08-12 |
| 2020-03-31 | $8.54M 10-Q · filed 2021-05-11 | $17.39M derived: sum of 2 quarters · filed 2021-05-11 | $22.88M derived: sum of 3 quarters · filed 2021-05-11 | |
| 2019-12-31 | $8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $14.34M derived: sum of 2 quarters · filed 2021-03-16 | $24.28M 10-K · filed 2021-03-16 | |
| 2019-09-30 | $5.49M 10-Q · filed 2020-11-10 | $15.43M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |